Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04550325 | Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 | PHASE1 | COMPLETED | 12 | — | — | Aug 5, 2020 | Nov 26, 2020 | Jan 5, 2021 | 4 | Israel |
Record adverse events, serious adverse events, and deaths
| Arm | Type | Description |
|---|---|---|
| Immune gamma globulin (IgG) | EXPERIMENTAL | Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion |
| Name | Type | Description |
|---|---|---|
| Kamada Anti-SARS-CoV-2 | BIOLOGICAL | Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods |
Inclusion Criteria: 1. Age ≥ 18 years 2. Laboratory confirmed SARS-CoV-2 infection by nasopharyngeal swab Real time polymerase chain reaction (RT-PCR) 3. Hospitalized for COVID-19 pneumonia 4. Dosing should be within 10 days of symptom start 5. Able and willing to sign informed consent form Exclus...